TERT and glioblastoma: The examination of genomic characteristics [36] across varying risk profiles, such as TERT promoter mutations [22] and MGMT promoter methylation levels, along with their associations with treatment outcomes (for instance, the efficacy of temozolomide), highlights the critical role of tailored therapeutic strategies in GBM treatment protocols [37].